Top Markets
Coin of the day
PT Kalbe Farma Tbk. PT Kalbe Farma Tbk.

PT Kalbe Farma Tbk.

KLBF
Rank in Stocks #6215
PT Kalbe Farma Tbk., an Indonesian pharmaceutical leader, along with its... PT Kalbe Farma Tbk., an Indonesian pharmaceutical leader, along with its subsidiaries, focuses on the development, manufacturing, and commercialization of pharmaceutical products across Indonesia. Its operations are structured into four primary divisions: Prescription Pharmaceuticals, Consumer Health, Nutritionals, and Distribution & Logistics. The company's diverse portfolio encompasses generic, branded, and licensed medications, including well-known names like Brainact, Cefspan, and Mycoral, which are supplied to hospitals, pharmacies, and various drugstores. Beyond prescription drugs, it offers non-prescription medicines, a range of energy and ready-to-drink beverages, dietary supplements, and other preventive health solutions. Kalbe Farma also produces specialized nutritional products tailored for all demographics, from infants to seniors, including expectant mothers and individuals with specific medical dietary needs. The firm extends contract services to other pharmaceutical companies, covering clinical study management, bioavailability/bioequivalence assessments, and analytical testing. Additionally, it provides animal health products and operates its own healthcare facilities, the Mitrasana Clinics. Its broad scope of activities further includes health screening, acting as an agent for biotechnology products, and the distribution of consumer items, medical devices, and cosmetics. The company also trades in medical and laboratory equipment and supplies, raw materials for pharmaceuticals, and consumables for hemodialysis therapy, in addition to offering advertising services. Founded in 1966, PT Kalbe Farma Tbk. is headquartered in Jakarta, Indonesia.
Share Price
$0.04784262
Market Cap
$2.16B
Change (1 day)
0.00%
Change (1 year)
-39.38%
Country
ID
Trade PT Kalbe Farma Tbk. (KLBF)

Category

P/B ratio for PT Kalbe Farma Tbk. (KLBF)
P/B ratio as of 2026 TTM: 0
According to PT Kalbe Farma Tbk. latest financial reports and stock price the company's current price-to-book ratio (TTM) is 0. At the end of 2026 the company had a P/B ratio of 0.
P/B ratio history for PT Kalbe Farma Tbk. from 2026 to 2026
P/B ratio at the end of each year
Year P/B Ratio Change
Not enough data for the provided dates.
P/B ratio for similar companies or competitors
Company P/B Ratio P/B Ratio Difference Country
31.0864 -
US
7.4766 -
US
-74.4354 -
US
8.4776 -
CH
8.008 -
US